Drugs / Senicapoc
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04372498 | Apr 2021 → Feb 2024 | dehydrated hereditary stomatocytosis | Boston Children's Hospital | Completed | No outcome recorded |
| Phase 25 trials · 1 met primary | ||||||
| Phase 2 | NCT07282210 | Jan 2026 → Nov 2028 expected | sickle cell disease | Biossil Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04804241 | Mar 2022 → Jun 2026 overdue | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | University of California, Davis | Recruiting | No outcome recorded |
| Phase 2 | NCT00861185 | Mar → Jul 2009 | exercise-induced bronchoconstriction | Icagen | Completed | No outcome recorded |
| Phase 2 | NCT00861211 | Oct 2008 → Mar 2009 | allergic asthma | Icagen | Completed | No outcome recorded |
| Phase 2 | NCT00040677 | Feb 2002 → Nov 2003 | sickle cell disease | Icagen | Completed | Met primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT00294541 | Feb 2006 → Jun 2007 | sickle cell disease | Icagen | Terminated | No outcome recorded |
| Phase 3 | NCT00102791 | Feb 2005 → Jun 2007 | sickle cell disease | Icagen | Terminated | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 0 | NCT07284069 Comparator | Mar 2026 → Nov 2028 expected | glioblastoma | Aarhus University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06714123 Comparator | Aug 2025 → Dec 2028 expected | idiopathic pulmonary fibrosis | Vejle Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04594668 Comparator | Apr 2020 → Apr 2021 | COVID-19, acute respiratory distress syndrome | University of Aarhus | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | senicapoc | “senicapoc (ICA-17043)” PMID 18192510 ↗ Jan 2008 |
| Known as | 2,2-bis-(4-fluorophenyl)-2-phenylacetamide | “Senicapoc (synonyms: ICA-17043; 2,2-bis-(4-fluorophenyl)-2-phenylacetamide)” NCT04372498 ↗ |
| Known as | ICA-17043 | “Senicapoc (ICA-17043) is a selective blocker of the intermediate-conductance calcium-activated potassium channel KCa3.1.” NCT07284069 ↗4“Senicapoc (synonyms: ICA-17043; 2,2-bis-(4-fluorophenyl)-2-phenylacetamide)” NCT04372498 ↗ |
| Known as | PF-05416266 | ChEMBL registry synonym — accepted as the source's own label CHEMBL405821 ↗ |
| Known as | SIL-8301 | “Senicapoc (SIL-8301)” NCT07282210 ↗ |
| Action | Inhibit | “ICA-17043 is a potent and specific inhibitor of a channel in human red blood cells (RBCs)” NCT00040677 ↗1“Intermediate conductance calcium-activated potassium channel protein 4 blocker” CHEMBL405821 ↗ |
| Modality | Small molecule | — CHEMBL405821 ↗ |
| Route | Oral | “Oral Senicapoc Administration” NCT00861185 ↗ |
| Target | KCNN4 | “Intermediate conductance calcium-activated potassium channel protein 4 blocker” CHEMBL405821 ↗ |